BIOTECanada confirmed a national team of industry leaders whose expertise will proliferate Canada’s $84 billion bio-economy at its 2010 annual general meeting in Montreal.
"The association is pleased to welcome these knowledgeable leaders, whose recognized achievements within the industry will bring formidable expertise to our board,” said Chair of the Board, Brad Thompson, president and CEO of Calgary’s Oncolytics Biotech Inc.
“BIOTECanada would also like to thank retiring board members for their service and dedication to the industry. Our volunteer Board of Directors is an active group with expertise across all sectors of biotechnology, representing both small and large biotechnology companies in Canada.”
The cross-sectoral team comes from companies across the country involved in industrial, agricultural, and health biotechnology including: crop DNA modification, animal health technologies, vaccines, oncology, cardiology, HIV/AIDS, depression, blood diseases, chronic pain, diabetes, and a range of serious conditions.
“As we face a new wave of technological innovation across agri-business and industrial and environmental biotechnologies, I am pleased to join this pan-Canadian group of industry leaders in raising awareness of the value our technologies bring to Canada’s future,” said Greg Penner, president and CEO of NeoVentures Biotechnology, an innovative agricultural biotechnology firm from London, Ontario.
The Board of Directors leads the association in implementing the recommendations of the industry strategy, Beyond Moose and Mountains. The strategy focuses on building Canada’s business and regulatory environment; increasing access to capital; and ensuring human resource needs are met.
“The Association has been a key leader on critical industry files including market access for biologics, and biotech product pricing in 2009. As a board member I look forward to taking part in shaping the continued growth of Canada’s bio-economy,” said Doug Janzen, president and CEO of Vancouver’s Cardiome Pharma Corp.
Source: BIOTECanada
"The association is pleased to welcome these knowledgeable leaders, whose recognized achievements within the industry will bring formidable expertise to our board,” said Chair of the Board, Brad Thompson, president and CEO of Calgary’s Oncolytics Biotech Inc.
“BIOTECanada would also like to thank retiring board members for their service and dedication to the industry. Our volunteer Board of Directors is an active group with expertise across all sectors of biotechnology, representing both small and large biotechnology companies in Canada.”
The cross-sectoral team comes from companies across the country involved in industrial, agricultural, and health biotechnology including: crop DNA modification, animal health technologies, vaccines, oncology, cardiology, HIV/AIDS, depression, blood diseases, chronic pain, diabetes, and a range of serious conditions.
“As we face a new wave of technological innovation across agri-business and industrial and environmental biotechnologies, I am pleased to join this pan-Canadian group of industry leaders in raising awareness of the value our technologies bring to Canada’s future,” said Greg Penner, president and CEO of NeoVentures Biotechnology, an innovative agricultural biotechnology firm from London, Ontario.
The Board of Directors leads the association in implementing the recommendations of the industry strategy, Beyond Moose and Mountains. The strategy focuses on building Canada’s business and regulatory environment; increasing access to capital; and ensuring human resource needs are met.
“The Association has been a key leader on critical industry files including market access for biologics, and biotech product pricing in 2009. As a board member I look forward to taking part in shaping the continued growth of Canada’s bio-economy,” said Doug Janzen, president and CEO of Vancouver’s Cardiome Pharma Corp.
Source: BIOTECanada
